LL-37
Last reviewed September 26, 2026
LL-37 is the only human cathelicidin-derived antimicrobial peptide. Research examines its dual role in direct microbial defense and in modulating the wider innate immune response.
Mechanism of action
Research describes LL-37 as disrupting microbial membranes directly while also acting as a signaling molecule that recruits and modulates immune cells.
- Membrane ActivityStudied for direct interaction with microbial membranes, a mechanism distinct from conventional antimicrobial pathways.
- Immune ModulationExplored for its role in recruiting immune cells and shaping the inflammatory response to a challenge.
- Route studied
- Subcutaneous
- Research status
- Preclinical
The available LL-37 literature consists mainly of reviews and laboratory studies of its antimicrobial and immune roles, and none of the cited work names a clinical trial of the peptide.
What the research covers
What research examines
- Direct antimicrobial membrane activity
- Antibiofilm properties in laboratory studies
- Innate immune modulation and immune cell recruitment
- Role in oral cavity health and disease
- Role in inflammatory bowel disease and lupus pathophysiology
- Membrane-active nanoparticle antimicrobial conjugates
Reported effects in studies
- Human safety data for LL-37 are limited
- Laboratory work has reported LL-37-induced cytotoxicity in human osteoblasts
- Reviews examine a possible role for LL-37 in cancer development
- Studied as a contributing molecule in the pathophysiology of systemic lupus erythematosus
What research protocols have used
Research protocols have used 100–500 mcg per administration, once daily (morning), in 4-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorCited research
- Cathelicidin LL-37: a multitask antimicrobial peptide.
Archivum immunologiae et therapiae experimentalis · 2010 · Review · PubMed 20049649
- LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity.
Pharmacological reports : PR · 2016 · Review · PubMed 27117377
- Antibiofilm properties of cathelicidin LL-37: an in-depth review.
World journal of microbiology & biotechnology · 2023 · Review · PubMed 36781570
- Cathelicidin LL-37 in Health and Diseases of the Oral Cavity.
Biomedicines · 2022 · Review · PubMed 35625823
- Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity.
Biochemical and biophysical research communications · 2024 · PubMed 38642493
Questions about LL-37
LL-37 is the only human cathelicidin-derived antimicrobial peptide. It is part of the innate immune system and has drawn research interest for a dual role: direct defense against microbes and modulation of the wider innate immune response. Reviews describe it as a multitask peptide with pleiotropic activity, and it is studied across several areas, including infection, inflammation, autoimmunity and cancer biology.
Research describes two main mechanisms. First, LL-37 interacts directly with microbial membranes and disrupts them, a mode of action distinct from conventional antimicrobial pathways. Second, it acts as a signaling molecule that recruits immune cells and shapes the inflammatory response to a challenge. This combination of direct membrane activity and immune signaling is a central theme in the published reviews of the peptide.
Published reviews have examined LL-37 antibiofilm properties, its roles in health and disease of the oral cavity, and its involvement in inflammatory bowel disease and systemic lupus erythematosus. Other work has explored its roles and mechanisms in cancer, as well as nanoantibiotic designs that attach membrane-active LL-37 to magnetic nanoparticles. Most of this literature is review-based or laboratory work rather than clinical trial data.
Human safety data are limited, and adverse events are not summarized in the cited studies. Laboratory research has reported LL-37-induced cytotoxicity in human osteoblasts, which was examined in connection with vitamin D-triggered hCAP18/LL-37 production. Reviews also discuss possible roles for LL-37 in cancer development and in the pathophysiology of systemic lupus erythematosus. These findings suggest that its biological effects depend on context.
Research protocols have used 100 to 500 mcg per administration by the subcutaneous route, once daily in the morning, in 4-week blocks followed by 4 weeks off. These figures describe what research protocols have used and are not a recommendation. Each CoreX order ships with a protocol guide for laboratory research reference. CoreX supplies LL-37 for laboratory research use only.
Ask about LL-37
Our research assistant answers questions about the science, the studied ranges, and our products. It can be wrong, and it does not give medical advice.
LL-37 at CoreX
Every batch is independently tested for identity and purity, and the certificate of analysis is tied to the lot number on your label.
Foundation
$69.00









